The Burden of Immunoglobulin Treatment
Research type
Research Study
Full title
The Burden of Immunoglobulin Treatment
IRAS ID
204620
Contact name
Teresa Kaufmann
Contact email
Sponsor organisation
BAXALTA US Inc.
Duration of Study in the UK
0 years, 5 months, 13 days
Research summary
The Burden of Treatment Questionnaire survey is part of a study that is being co-organized by The International Patient Organization for Primary Immunodeficiencies (IPOPI) and its National Member Organizations (NMOs), in collaboration with the University of Sheffield. IPOPI works as a global advocate for the PID patient community with the help of its NMOs. The study is funded by the pharmaceutical company BAXALTA US Inc. (hereinafter Sponsor) and managed by a clinical research organization called PAREXEL. The purpose of this survey is to collect information from adult patients (18 years and older) who have been diagnosed with a PID and are currently receiving Ig treatment either intravenously (IV) or subcutaneously (SC). The survey will ask about their current Ig treatment, including how they take their medication, their thoughts and opinions about the treatment for their PID, and their condition and health status during their current Ig therapy. It also contains some demographic questions (e.g. employment status).
REC name
London - Brighton & Sussex Research Ethics Committee
REC reference
16/LO/0729
Date of REC Opinion
20 Apr 2016
REC opinion
Further Information Favourable Opinion